Shu Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shu Wang has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Douglas S. Scherr
Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York
2 shared publicationsHelen Xu
Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York
2 shared publications- Jianxing Li
Department of Urology, Beijing Tsinghua changgung Hospital, Beijing, China
2 shared publications - Jim Hu
Department of Urology, NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, NY
2 shared publications Kyle A. Blum
Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York
2 shared publicationsMax Drescher
Division of Urology, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA
2 shared publications
Latest Publications
- 1 November 2026
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 13 (6) , 669-670
Reply by Authors
- 1 November 2026
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 13 (6) , 669-670
Reply by Authors
- 1 November 2026
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 13 (6) , 663-670
National Patterns and Predictors of Perioperative Intravesical Chemotherapy Use Following Nephroureterectomy for Upper Tract Urothelial Carcinoma
Intravesical chemotherapy (IC) administered perioperatively after nephroureterectomy (NUx) for upper tract urothelial carcinoma (UTUC) reduces intravesical recurrence based on two randomized trials and is endorsed by contemporary practice guidelines. However, real-world adoption of this intervention remains poorly defined. We evaluated national utilization trends and identified predictors of perioperative IC use following NUx. Using the National Cancer Database, we identified patients with non-metastatic UTUC who underwent NUx between 2013 and 2022. Perioperative IC was defined as chemotherapy administered within 48 hours of surgery. Temporal trends were assessed using the Cochran-Armitage test. Multivariable logistic regression was used to identify factors independently associated with IC receipt. Among 14,808 eligible patients, only 1,032 (7.0%) received perioperative IC. Utilization increased significantly over time, from 1.1% in 2013 to 16.6% in 2022 (p<0.001). On multivariable analysis, treatment at an academic (OR 2.47, 95% CI 2.09-2.91) or comprehensive cancer program (OR 2.24, 95% CI 1.86-2.69), later year of diagnosis (OR 1.37 per year, 95% CI 1.33-1.41), and ureteral tumor location (OR 1.22, 95% CI 1.06-1.40) were associated with higher odds of IC use. Hispanic ethnicity (OR 0.39, 95% CI 0.26-0.59), higher clinical T stage, and open surgical approach were associated with significantly lower odds of IC receipt. Despite level 1 evidence and guideline endorsement, perioperative intravesical chemotherapy after nephroureterectomy remains infrequently used in the United States. Persistent disparities in adoption highlight a substantial evidence-to-practice gap and underscore opportunities for targeted implementation strategies to improve equitable delivery of guideline-supported care.
- 1 November 2026
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 13 (6) , 663-670
National Patterns and Predictors of Perioperative Intravesical Chemotherapy Use Following Nephroureterectomy for Upper Tract Urothelial Carcinoma
Intravesical chemotherapy (IC) administered perioperatively after nephroureterectomy (NUx) for upper tract urothelial carcinoma (UTUC) reduces intravesical recurrence based on two randomized trials and is endorsed by contemporary practice guidelines. However, real-world adoption of this intervention remains poorly defined. We evaluated national utilization trends and identified predictors of perioperative IC use following NUx. Using the National Cancer Database, we identified patients with non-metastatic UTUC who underwent NUx between 2013 and 2022. Perioperative IC was defined as chemotherapy administered within 48 hours of surgery. Temporal trends were assessed using the Cochran-Armitage test. Multivariable logistic regression was used to identify factors independently associated with IC receipt. Among 14,808 eligible patients, only 1,032 (7.0%) received perioperative IC. Utilization increased significantly over time, from 1.1% in 2013 to 16.6% in 2022 (p<0.001). On multivariable analysis, treatment at an academic (OR 2.47, 95% CI 2.09-2.91) or comprehensive cancer program (OR 2.24, 95% CI 1.86-2.69), later year of diagnosis (OR 1.37 per year, 95% CI 1.33-1.41), and ureteral tumor location (OR 1.22, 95% CI 1.06-1.40) were associated with higher odds of IC use. Hispanic ethnicity (OR 0.39, 95% CI 0.26-0.59), higher clinical T stage, and open surgical approach were associated with significantly lower odds of IC receipt. Despite level 1 evidence and guideline endorsement, perioperative intravesical chemotherapy after nephroureterectomy remains infrequently used in the United States. Persistent disparities in adoption highlight a substantial evidence-to-practice gap and underscore opportunities for targeted implementation strategies to improve equitable delivery of guideline-supported care.
- Open Access
- 22 September 2026
- Published by Wiley in BJUI Compass
- Vol. 7 (9) , e70275
Comparing diagnostic prostate cancer biomarkers using a framework of clinically meaningful criteria
Objectives: To synthesize existing biomarker literature and generate a framework for meaningful comparison between five commonly used diagnostic prostate cancer biomarkers—prostate health index ( phi ), 4KScore, SelectMDx, ExoDx and MyProstate Score (MPS)—to provide evidence of greatest practical value to providers managing men with an elevated prostate‐specific antigen (PSA) who are considering prostate biopsy. Materials and methods: Ten biomarker characteristics reflecting validity , usability and utility were designated as most clinically salient in guiding diagnostic prostate cancer biomarker selection. Whereas usability reflects how well a biomarker individualizes risk and optimizes patient concerns, utility reflects a biomarker's clinical usefulness. A systematic review of the biomarker literature from 2010 to 2022 was performed, and the criteria for each biomarker characteristic were first inductively defined and subsequently determined for each respective biomarker. Results: Nearly all biomarkers possess wide validity , with phi , 4KScore and MPS validated in Black populations. Compared to other biomarkers, 4KScore had the best usability . For urine‐based biomarkers, the better usability of ExoDx versus MPS is offset by its worse validity and utility . All serum‐based biomarkers have very high discriminative accuracy and were consequently more accurate in detecting high‐grade prostate cancer versus urine‐based biomarkers. Overall, 4KScore had the best utility . Conclusion: Our framework enables meaningful comparison of diagnostic prostate cancer biomarkers using criteria most salient to patients and clinicians. We demonstrate that the 4KScore currently possesses the best overall features; despite emerging evidence, more clinical utility, comparative and non‐White population validation studies are needed.
- 22 September 2026
- Published by Wiley in BJUI Compass
- Vol. 7 (9) , e70275
Open AccessComparing diagnostic prostate cancer biomarkers using a framework of clinically meaningful criteria
Objectives: To synthesize existing biomarker literature and generate a framework for meaningful comparison between five commonly used diagnostic prostate cancer biomarkers—prostate health index ( phi ), 4KScore, SelectMDx, ExoDx and MyProstate Score (MPS)—to provide evidence of greatest practical value to providers managing men with an elevated prostate‐specific antigen (PSA) who are considering prostate biopsy. Materials and methods: Ten biomarker characteristics reflecting validity , usability and utility were designated as most clinically salient in guiding diagnostic prostate cancer biomarker selection. Whereas usability reflects how well a biomarker individualizes risk and optimizes patient concerns, utility reflects a biomarker's clinical usefulness. A systematic review of the biomarker literature from 2010 to 2022 was performed, and the criteria for each biomarker characteristic were first inductively defined and subsequently determined for each respective biomarker. Results: Nearly all biomarkers possess wide validity , with phi , 4KScore and MPS validated in Black populations. Compared to other biomarkers, 4KScore had the best usability . For urine‐based biomarkers, the better usability of ExoDx versus MPS is offset by its worse validity and utility . All serum‐based biomarkers have very high discriminative accuracy and were consequently more accurate in detecting high‐grade prostate cancer versus urine‐based biomarkers. Overall, 4KScore had the best utility . Conclusion: Our framework enables meaningful comparison of diagnostic prostate cancer biomarkers using criteria most salient to patients and clinicians. We demonstrate that the 4KScore currently possesses the best overall features; despite emerging evidence, more clinical utility, comparative and non‐White population validation studies are needed.
- 1 July 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 320 (1)
Combination of Radiation Therapy and Irreversible Electroporation for Intermediate-Risk Prostate Cancer (RTIRE): A Phase 1 Trial
Treatment of participants with intermediate-risk prostate cancer with focal irreversible electroporation and radiation therapy was technically feasible and showed acceptable patient-reported outcomes and no severe adverse events over 1 year.
- 1 July 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 320 (1)
Combination of Radiation Therapy and Irreversible Electroporation for Intermediate-Risk Prostate Cancer (RTIRE): A Phase 1 Trial
Treatment of participants with intermediate-risk prostate cancer with focal irreversible electroporation and radiation therapy was technically feasible and showed acceptable patient-reported outcomes and no severe adverse events over 1 year.
- Open Access
- 1 August 2025
- Published by Wolters Kluwer Health in Current Urology
- Vol. 19 (6) , 429-430
Trends of upgrading and upstaging of grade group 1 prostate cancer at radical prostatectomy: NCDB and SEER results from 2010 to 2021
- 1 August 2025
- Published by Wolters Kluwer Health in Current Urology
- Vol. 19 (6) , 429-430
Open AccessTrends of upgrading and upstaging of grade group 1 prostate cancer at radical prostatectomy: NCDB and SEER results from 2010 to 2021
- 3 August 2022
- Published by Wiley in The Prostate
- Vol. 82 (16) , 1520-1528
Prostate cancer grade downgrading at time of prostatectomy provides risk‐stratification insight into future tumor behavior after prostatectomy
Background: Prostate biopsy (Bx) sampling‐based diagnosis of prostate cancer (PCa) has well‐described inaccuracy when compared against whole gland analysis upon prostatectomy. Although upgrading of PCa Grade Group (GG) is often described, the occurrence and prognostic implications of downgrading PCa GG at the time of radical prostatectomy (RP) is less understood. Our objective was to evaluate whether downgrading PCa GG at the time of RP was associated with future tumor behavior.Methods: The SEER database was searched from 2010 to 2017 and patients were included if they were assigned pathological grades on both Bx and RP specimen. Patients were stratified into Bx GG > RP GG and Bx GG ≤ RP GG groups, and tumor behavior after treatment was examined. Cox regression was used for the survival analysis.Results: Here, 99,835 patients were included in this study. A total of 18,516 (18.5%) patients encountered downgrading from Bx GG to RP GG. A downgrading of 1 grade occurred in 13,969 (75.4%) of these patients and of 2 or more grades occurred in 4547 (24.6%) patients. A history of higher Bx GG compared with RP GG increased the risk of cancer‐specific mortality (CSM) for each given RP GG controlling for age, race, preop prostate‐specific antigen level, percentage of positive biopsy cores, and pathologic TNM stages. Specifically, a history of high Bx GG conferred a 45% increased risk of CSM for any given RP GG (hazard ratio = 1.45 95% confidence interval = 1.16–1.82, p < 0.001).Conclusion: A history of higher Bx GG, and hence downgrading at the time of RP, demonstrates some value as a risk‐stratification tool for future cancer outcomes after prostatectomy.
- 3 August 2022
- Published by Wiley in The Prostate
- Vol. 82 (16) , 1520-1528
Prostate cancer grade downgrading at time of prostatectomy provides risk‐stratification insight into future tumor behavior after prostatectomy
Background: Prostate biopsy (Bx) sampling‐based diagnosis of prostate cancer (PCa) has well‐described inaccuracy when compared against whole gland analysis upon prostatectomy. Although upgrading of PCa Grade Group (GG) is often described, the occurrence and prognostic implications of downgrading PCa GG at the time of radical prostatectomy (RP) is less understood. Our objective was to evaluate whether downgrading PCa GG at the time of RP was associated with future tumor behavior.Methods: The SEER database was searched from 2010 to 2017 and patients were included if they were assigned pathological grades on both Bx and RP specimen. Patients were stratified into Bx GG > RP GG and Bx GG ≤ RP GG groups, and tumor behavior after treatment was examined. Cox regression was used for the survival analysis.Results: Here, 99,835 patients were included in this study. A total of 18,516 (18.5%) patients encountered downgrading from Bx GG to RP GG. A downgrading of 1 grade occurred in 13,969 (75.4%) of these patients and of 2 or more grades occurred in 4547 (24.6%) patients. A history of higher Bx GG compared with RP GG increased the risk of cancer‐specific mortality (CSM) for each given RP GG controlling for age, race, preop prostate‐specific antigen level, percentage of positive biopsy cores, and pathologic TNM stages. Specifically, a history of high Bx GG conferred a 45% increased risk of CSM for any given RP GG (hazard ratio = 1.45 95% confidence interval = 1.16–1.82, p < 0.001).Conclusion: A history of higher Bx GG, and hence downgrading at the time of RP, demonstrates some value as a risk‐stratification tool for future cancer outcomes after prostatectomy.
- 25 January 2022
- Published by Wolters Kluwer Health in Zhonghua Wei Chang Wai Ke Za Zhi = Chinese Journal of Gastrointestinal Surgery
- Vol. 25 (1) , 22-29
[Research progress of colorectal surgery in 2021 and future prospects].
In recent years, with the wide application of immune score and liquid biopsy to guide the accurate diagnosis and precise treatment of colorectal cancer, colorectal surgery develops more rationally and scientifically. The strategy of organ function protection in colorectal surgery gradually attracts more and more attention. The continuous development of comprehensive treatments, such as targeted therapy and immunotherapy, provides more choices for colorectal cancer patients. Several significant progress in surgical strategies for benign colorectal diseases challenges the traditional concepts as well. The advances in medical science and the innovation of concepts and ideas set high new standards for the development of colorectal surgery in China. Efforts are required to improve the standardization of diagnosis and treatment of colorectal disease. There is still a long way to go to explore patient-centered new technologies, new concepts and new fields of accurate diagnosis and precise treatment in colorectal surgery.
- 25 January 2022
- Published by Wolters Kluwer Health in Zhonghua Wei Chang Wai Ke Za Zhi = Chinese Journal of Gastrointestinal Surgery
- Vol. 25 (1) , 22-29
[Research progress of colorectal surgery in 2021 and future prospects].
In recent years, with the wide application of immune score and liquid biopsy to guide the accurate diagnosis and precise treatment of colorectal cancer, colorectal surgery develops more rationally and scientifically. The strategy of organ function protection in colorectal surgery gradually attracts more and more attention. The continuous development of comprehensive treatments, such as targeted therapy and immunotherapy, provides more choices for colorectal cancer patients. Several significant progress in surgical strategies for benign colorectal diseases challenges the traditional concepts as well. The advances in medical science and the innovation of concepts and ideas set high new standards for the development of colorectal surgery in China. Efforts are required to improve the standardization of diagnosis and treatment of colorectal disease. There is still a long way to go to explore patient-centered new technologies, new concepts and new fields of accurate diagnosis and precise treatment in colorectal surgery.
- 1 January 2022
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 207 (1) , 93
Editorial Comment
- 1 January 2022
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 207 (1) , 93
Editorial Comment
- Open Access
- 1 February 2020
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 46 (1) , 70-80
Upper urinary tract stone compositions: the role of age and gender
To analyze the compositions of upper urinary tract stones and investigate their distributions in different gender and age groups. Patients diagnosed with upper urinary tract stone disease between December 2014 and March 2018 were retrospectively reviewed. Patient's age, gender, BMI, comorbidities, stone event characteristics, and compositions were collected, and proportions of stone components in different gender and age groups were analyzed. A total of 1532 stone analyses were performed (992 from males and 540 from females). The mean age was younger in males (p<0.001). Males included more cases with larger BMI, hyperuricemia, and obesity, while females had more urinary tract infections. Multiple components were present in 61.8% of stones. Calcium oxalate (CaOx) (67.0%) was the most common component, followed by uric acid (UA) (11.8%), infection stone (11.4%), calcium phosphate (CaP) (8.0%), cystine (1.1%), brushite (0.4%), and 2,8-dihydroxyadenine (0.2%). Men contributed with more CaOx stones than women at age 30-49 years (all p<0.01) and more UA stones at 30-59 years (all p<0.05). Women contributed with more infection stones than men in age groups 30-49 and 60-69 years (all p<0.05), and more CaP stones at 30-49 years. The prevalence peak was 50-59 years in men and 60-69 years in women. Both genders had the lowest prevalence in adolescence. Prevalence of UA stones increased while that of infection stones decreased with aging in both genders. Age and sex had a strong association with distribution of stone compositions in this Chinese cohort.
- 1 February 2020
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 46 (1) , 70-80
Open AccessUpper urinary tract stone compositions: the role of age and gender
To analyze the compositions of upper urinary tract stones and investigate their distributions in different gender and age groups. Patients diagnosed with upper urinary tract stone disease between December 2014 and March 2018 were retrospectively reviewed. Patient's age, gender, BMI, comorbidities, stone event characteristics, and compositions were collected, and proportions of stone components in different gender and age groups were analyzed. A total of 1532 stone analyses were performed (992 from males and 540 from females). The mean age was younger in males (p<0.001). Males included more cases with larger BMI, hyperuricemia, and obesity, while females had more urinary tract infections. Multiple components were present in 61.8% of stones. Calcium oxalate (CaOx) (67.0%) was the most common component, followed by uric acid (UA) (11.8%), infection stone (11.4%), calcium phosphate (CaP) (8.0%), cystine (1.1%), brushite (0.4%), and 2,8-dihydroxyadenine (0.2%). Men contributed with more CaOx stones than women at age 30-49 years (all p<0.01) and more UA stones at 30-59 years (all p<0.05). Women contributed with more infection stones than men in age groups 30-49 and 60-69 years (all p<0.05), and more CaP stones at 30-49 years. The prevalence peak was 50-59 years in men and 60-69 years in women. Both genders had the lowest prevalence in adolescence. Prevalence of UA stones increased while that of infection stones decreased with aging in both genders. Age and sex had a strong association with distribution of stone compositions in this Chinese cohort.